Leen Van de Sande
Doctoral fellow, Department of Surgery, Faculty of Medicine and Health Sciences, UGent
Principal investigator: prof. Wim Ceelen (MD, PhD)
Over 85% of women with ovarian cancer (OC) will develop a peritoneal recurrence after initial therapy. The prognosis of patients with recurrent disease is poor, with a median survival ranging from 12 to 24 months. Most of these patients ultimately develop platinum resistant disease (PROC). Current systemic therapy results in a very modest improvement of progression free and overall survival. The addition of locoregional, intraperitoneal (IP) therapy may improve disease control in recurrent OC. Recently, pressurized intraperitoneal aerosol therapy (PIPAC) was added to the therapeutic arsenal. This novel technique allows repeated laparoscopy aided aerosol delivery of anticancer drugs to the peritoneal cavity. Abraxane™ (nab-pac, Celgene) is a novel 130 nm, albumin-bound (nab™) nanoparticle formulation of paclitaxel which has noteworthy single-agent activity and a favourable toxicity profile when used systemically in PROC.
The aim of this research is 1) to study the safety and efficacy of IV Taxol combined with repeated PIPAC using nab-pac and 2) to optimize the PIPAC-technique in a rabbit model.
The study consists of three parts. First, the structure, stability and antitumor activity of nab-pac against SKOV3 cells will be assessed in vitro after aerosolization, and compared with the native product. Subsequently, a phase I/IIa and a phase IIb clinical study will be performed to study the safety and efficacy of IV Taxol combined with repeated PIPAC using nab-pac. In the last part a rabbit model will be created using VX2 cells to optimize the PIPAC-technique.
Vakgroep Heelkunde - BLOK B verdieping -1, Corneel Heymanslaan 10, 9000 Gent